NCT03284723: PF-06804103 Dose Escalation in HER2 Positive Solid Tumors

NCT03284723
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known CNS disease including, but not limited to, metastases
https://ClinicalTrials.gov/show/NCT03284723

Comments are closed.

Up ↑